Crospovidone IR Granules are pharmaceutical excipient granules based on cross-linked polyvinylpyrrolidone, also known as cross-linked PVP, polyvinylpolypyrrolidone (PVPP), and crospovidone. Crospovidone has CAS Number 9003-39-8 and the polymeric formula (C₆H₉NO)ₙ. According to the current USP-NF monograph, crospovidone is a water-insoluble synthetic cross-linked homopolymer of N-vinyl-2-pyrrolidone and contains 11.0%–12.8% nitrogen calculated on the dried basis. USP also identifies two types of crospovidone according to particle size: Type A and Type B.
Crospovidone IR Granules are a granulated pharmaceutical excipient format intended for formulation applications where an immediate-release dosage form is being developed. The term IR refers to the intended immediate-release formulation or finished granule system and does not represent a separate chemical grade of crospovidone.
Crospovidone itself is a cross-linked and water-insoluble polymer. Its physical and functional characteristics make it useful in oral solid formulation development, particularly where rapid formulation breakup and dispersion are required.
For a commercial IR granule product, the exact particle size, granule distribution, moisture, density and release characteristics should be controlled according to the approved product specification.
Cross-linked polyvinylpyrrolidone is commonly referred to as crospovidone or polyvinylpolypyrrolidone. It is structurally different from povidone because cross-linking makes the polymer insoluble in water.
USP defines crospovidone as a water-insoluble synthetic cross-linked homopolymer of N-vinyl-2-pyrrolidone. The current USP-NF specification identifies CAS 9003-39-8 and a nitrogen content of 11.0%–12.8% calculated on the dried basis.
The cross-linked structure is important for its pharmaceutical functionality. Unlike soluble povidone, crospovidone remains insoluble and can take up liquid within a formulation.
Immediate-release formulations are designed to release their incorporated active ingredient without the intentional delay or prolonged-release mechanism characteristic of modified-release systems.
Crospovidone can be incorporated into immediate-release oral solid formulations as a disintegrant. Its water-insoluble cross-linked structure can facilitate liquid uptake and contribute to tablet or granule breakup when appropriately formulated.
The actual dissolution and release behavior of a finished IR product depends on many formulation factors, including active ingredient properties, particle size, excipient selection, compression conditions, coating status, manufacturing process and dosage-form design.
Therefore, the designation “IR” should not be interpreted as a universal dissolution specification for crospovidone itself.
Crospovidone IR Granules can be developed with controlled physical characteristics to support pharmaceutical processing. Depending on the actual product specification, relevant characteristics may include:
Particle size is particularly relevant to crospovidone because USP recognizes Type A and Type B materials according to particle size.
Exact D10, D50, D90, density and flow values should be stated only when they are part of the actual approved specification or certificate of analysis.
Crospovidone is commonly selected when a formulation requires a cross-linked PVP excipient with water-insoluble characteristics.
In an immediate-release tablet or multiparticulate system, appropriate excipient selection can influence wetting, liquid penetration, disintegration and subsequent release. Crospovidone can contribute to the disintegration stage of the formulation.
However, crospovidone should not be described as independently guaranteeing immediate release. The final release profile is determined by the complete formulation and manufacturing process.
Quality control of crospovidone can involve identity, nitrogen content, moisture-related testing, residue on ignition, impurities and other applicable pharmacopoeial requirements.
The current USP-NF monograph specifies nitrogen content at 11.0%–12.8% on the dried basis and identifies Type A and Type B according to particle size.
USP also maintains a Crospovidone Reference Standard, confirming its established position within the USP excipient reference-standard system.
Where a product is marketed as USP/NF compliant, the actual grade and current specification should support the claim.
Crospovidone is water-insoluble. FCC describes crospovidone as a white to off-white, hygroscopic, free-flowing material and states that it is insoluble in water and other common solvents.
For a granulated product, however, the appearance and flow characteristics can differ from those of the underlying powder depending on granulation and processing conditions.
Crospovidone IR Granules may be considered for:
The suitability of a particular grade should be established through formulation development and product-specific performance testing.
When developing an immediate-release formulation using Crospovidone IR Granules, formulators may evaluate particle size, excipient concentration, active ingredient properties, lubricant level, compression force, tablet hardness, disintegration time and dissolution performance.
Granule size can influence powder blending and processing. Moisture can affect physical properties and manufacturing behavior. Compression conditions can influence tablet porosity and liquid penetration.
Consequently, the final formulation should be evaluated as a complete system rather than relying on the name “IR Granules” alone.
The finished Crospovidone IR Granules should be evaluated against the applicable product specification. Important product-specific parameters may include identification, nitrogen content, moisture, residue on ignition, particle-size distribution, bulk density, tapped density and other functional characteristics.
Where the material is supplied as a finished immediate-release granule system, dissolution or disintegration requirements should be established from the actual formulation and approved product specification rather than assigned as generic crospovidone values.
Crospovidone IR Granules provide a pharmaceutical excipient format based on cross-linked polyvinylpyrrolidone for immediate-release formulation development. Crospovidone has CAS Number 9003-39-8, polymeric formula (C₆H₉NO)ₙ and is defined by USP-NF as a water-insoluble synthetic cross-linked homopolymer of N-vinyl-2-pyrrolidone. The current USP-NF monograph specifies nitrogen at 11.0%–12.8% on the dried basis and recognizes Type A and Type B according to particle size.
For commercial IR granules, particle size, moisture, density, flow properties, disintegration and dissolution characteristics should be controlled according to the actual approved product specification and certificate of analysis.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 0.5% |